Læknablaðið - 15.06.1999, Side 15

LÆKNABLAÐIÐ 1999; 85
515
Helo P, et al. Helsinki Heart Study: primary-prevention trial
with gemfibrozil in middle-aged men with dyslipidemia. N
Engl J Med 1987; 317: 1237-45.
7. Scandinavian Simvastatin Survival Study Group. Rando-
mised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Sur-
vival Study (4S). Lancet 1994; 344: 1383-9.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, LorimerAR, Mac-
Farlane PW, et al. Prevention of coronary heart disease with
pravastatin in men with hypercholesterolemia. West of
Scotland Coronary Prevention Study. N Engl J Med 1995;
333:1301-7.
9. Brown MS, Goldstein JL. Heart attacks gone with the cen-
tury? Science 1996; 272: 629.
10. Pearson TA, Peters TD. The treatment gap in coronary
artery disease and heart failure. Community standards and
the post-discharge patient. Am J Cardiol 1997; 80: 45H-
52H.
11. ASPIRE Steering Group. A British Cardiac Society survey
of the potential for the secondary prevention of coronary
disease: ASPIRE (Action in Secondary Prevention through
Intervention to Reduce Events). Principal Resuls. Heart
1996; 75: 334-42.
12. Sigurðsson EL, Jónsson JS, Þorgeirsson G. Hvemig er kól-
esteróllækkandi lyfjameðferð háttað meðal íslenskra krans-
æðasjúklinga. Læknablaðið 1999; 85: 109-19.
13. Clarke TJ, Mayo G, Price P, Fitzgerald G. Suppression of
thromboxane A2 but not of systemic prostacyclin by con-
trolled-release aspirin. N Engl J Med 1991; 325: 1137-41.
14. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smither-
man TC, Doherty JE 3d, et al. Protective effects of aspirin
against acute myocardial infarction and death in men with
unstable angina. N Engl J Med 1983; 309: 396-403.
15. The RISC Group. Risk of myocardial infarction and death
during treatment with low dose aspirin and intravenous
heparin in men with unstable coronary artery disease.
Lancet 1990; 336: 827-30.
16. Antiplatelet Trialists' Collaboration. Secondary prevention
of vascular disease by prolonged antiplatelet treatment.
BMJ 1988:296: 320-31.
17. Juul-Möller S, Edvardsson N, Jahnmarz B, Rosén A,
Sörensen S, Ömblus R. for the SAPAT group. Double-blind
trial of aspirin in primary prevention of myocardial infarc-
tion in patients with stabel chronic angina pectoris. Lancet
1992:340: 1421-5.
18. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner
B, Speizer FE, et al. A prospective study of aspirin use and
primary prevention of cardiovascular disease in women.
JAMA 1991:266: 521-7.
19. Steering committee of the physicians' health study research
group. Final report on the aspirin component of the ongoing
physicians' health study. N Engl J Med 1989; 321: 129-35.
20. Antiplatelet Trialists Collaboration. Collaborative overview
of randomized trials of antiplatelet treatment, I: prevention
of fascular death, MI and stroke by prolonged antiplatelet
therapy in different categories of patients. BMJ 1994; 308:
235-46.
21. Fuster V, Cohen M, Halperin J. Aspirin in the prevention of
coronary disease. N Engl J Med 1989; 321: 183-5.
22. Hennekens CH, Albert CM, Godfried SL, Gaziano JM,
Buring JE. Adjunctive drug therapy of acute myocardial in-
farction-evidence from clinical trials. N Engl J Med 1996;
335: 1660-7.
23. Vogel RA. Risk factor intervention and coronaiy artery
disease: clinical strategies. Coronary Artery Disease 1995;
6: 466-71.
24. Schwartz LM, Fisher ES, Tosteson NA, Woloshin S, Chang
CH, Vimig BA, et al. Treatment and health outcomes of
women and men in a cohort with coronary artery disease.
Arch Intem Med 1997; 157: 1545-51.
25. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after
myocardial infarction: influence of first-year clinical course
on long-term effectiveness. Ann Intem Med 1993; 118: 99-
105.
26. Frishman WH, Furberg CD, Friedewald WT. Beta-adrener-
gic blockade for survivors of acute myocardial infarction. N
EnglJMed 1984:310: 830-7.
27. Moss AJ, Benhorin J. Prognosis and management after a
first myocardial infarction. N Engl J Med 1990; 323: 548-
50.
28. Pfeffer MA, Braunwld E, Moye LA, Basta L, Brown EJ,
Cuddy TE, et al. Effect of captopril on mortality and morbi-
dity in patients with left ventricular dysfunction after myo-
cardial infarction. Results of the survival and ventricular
enlargement trial. The SAVE Investigators. N Engl J Med
1992;327:669-77.
29. Effects of estrogen or estrogen/progestin regimens on heart
disease risk factors in postmenopausal women. The Post-
menopausal Estrogen/Progestin Interventions (PEPI) Trial.
The Writing Group for the PEPI Trial. JAMA 1995; 273:
199-208.
30. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs
B, et al. Randomized trial of estrogen plus progestin for
secondary prevention of coronary heart disease in post-
menopausal women. Heart and Estrogen/Progestin Re-
placement Study (HERS) Research Group. JAMA 1998;
280: 605-13.